Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of UB-612 Vaccine in Healthy Adults
NCT04545749Phase 1Completed
- Sponsor
- United Biomedical, Inc.
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of UB-612 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by United Biomedical, Inc. Primary endpoint: Safety of UB-612 vaccine. Started Sep 2020; status: completed.
02
Drugs
UB-612
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04545749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545749.